Impact Biomedical (IBO) Retained Earnings (2022 - 2026)

Impact Biomedical (IBO) has reported Retained Earnings for 5 consecutive years, with $63.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings rose 218.52% year-over-year to $63.2 million; the trailing twelve-month figure through Jun 2026 stood at $63.2 million (up 218.52% YoY), and the FY2025 full-year result was $61.7 million, up 47.44% from the prior year.
• Retained Earnings held at $63.2 million in Q2 2026 per IBO's latest filing, from $63.2 million in the prior quarter.
• Across five years, Retained Earnings topped out at $63.2 million in Q1 2026 and bottomed at -$54.8 million in Q3 2025.
• Historically, Retained Earnings has averaged $20.7 million across 5 years, with a median of $38.1 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Retained Earnings jumped 541.89% in 2023, then sank 239.8% in 2025.
• Over 5 years, Retained Earnings stood at -$8.6 million in 2022, then surged by 541.89% to $38.1 million in 2023, then rose by 9.82% to $41.9 million in 2024, then surged by 47.44% to $61.7 million in 2025, then advanced by 2.33% to $63.2 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered $63.2 million, $63.2 million, and $61.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.